TipRanks
Advertisement
Advertisement

GILD Stock Latest News

Gilead: Buy Rating Reiterated on Emvistegrast Momentum, Durable HIV Core and Emerging Oncology Growth; $174 Price Target Maintained
RatingsGilead: Buy Rating Reiterated on Emvistegrast Momentum, Durable HIV Core and Emerging Oncology Growth; $174 Price Target Maintained
16h ago
GILD
Gilead price target raised to $172 from $168 at BofA
PremiumThe Fly
Gilead price target raised to $172 from $168 at BofA
18h ago
GILD
Ahmad Reaffirms Buy on Gilead as Emvistegrast Data Boosts Pipeline Outlook and Supports Raised $172 Price Target
PremiumRatings
Ahmad Reaffirms Buy on Gilead as Emvistegrast Data Boosts Pipeline Outlook and Supports Raised $172 Price Target
19h ago
GILD
Gilead to present new data across HIV, antiviral research at IDWeek
PremiumThe Fly
Gilead to present new data across HIV, antiviral research at IDWeek
2d ago
GILD
AI Models Split on Gilead Sciences as Earnings Volatility Meets Strong Cash Flow
PremiumAI Analyst Ratings
AI Models Split on Gilead Sciences as Earnings Volatility Meets Strong Cash Flow
4d ago
GILD
Private Markets: TypeSafe AI, Oratomic secure fresh capital
PremiumThe FlyPrivate Markets: TypeSafe AI, Oratomic secure fresh capital
5d ago
ZS
ABM
Vir Biotechnology enters collaboration, license agreement with Gilead
Premium
The Fly
Vir Biotechnology enters collaboration, license agreement with Gilead
7d ago
VIR
GILD
Gilead price target raised to $168 from $162 at BofA
Premium
The Fly
Gilead price target raised to $168 from $162 at BofA
9d ago
GILD
Gilead price target raised to $126 from $123 at RBC Capital
PremiumThe Fly
Gilead price target raised to $126 from $123 at RBC Capital
13d ago
GILD
Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)
PremiumTipRanks Newswire
Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)
14d ago
LLY
AMGN
Early notable gainers among liquid option names on October 7th
PremiumThe Fly
Early notable gainers among liquid option names on October 7th
14d ago
KR
MPC
Gilead price target raised to $158 from $150 at Truist
PremiumThe Fly
Gilead price target raised to $158 from $150 at Truist
14d ago
GILD
Gilead price target lowered to $163 from $165 at Morgan Stanley
PremiumThe FlyGilead price target lowered to $163 from $165 at Morgan Stanley
14d ago
GILD
Gilead price target raised to $170 from $160 at JPMorgan
Premium
The Fly
Gilead price target raised to $170 from $160 at JPMorgan
14d ago
GILD
Cognizant announces five-year extension of its work with Gilead Sciences
Premium
The Fly
Cognizant announces five-year extension of its work with Gilead Sciences
15d ago
CTSH
GILD
Nurix Therapeutics announces second research term extension with Gilead
PremiumThe Fly
Nurix Therapeutics announces second research term extension with Gilead
16d ago
GILD
NRIX
Gilead put volume heavy and directionally bearish
PremiumThe Fly
Gilead put volume heavy and directionally bearish
20d ago
GILD
Michael Yee Reiterates Buy on Gilead, Highlighting Yeztugo-Driven HIV Growth and Maintaining Unchanged $175 Price Target
PremiumRatings
Michael Yee Reiterates Buy on Gilead, Highlighting Yeztugo-Driven HIV Growth and Maintaining Unchanged $175 Price Target
26d ago
GILD
3 Best ETFs Offering 10%+ Upside, Picked by AI Analyst
PremiumMarket News
3 Best ETFs Offering 10%+ Upside, Picked by AI Analyst
29d ago
VZ
BMY
Gilead announces expanded scope of licensing agreements for lenacapavir
PremiumThe FlyGilead announces expanded scope of licensing agreements for lenacapavir
1M ago
GILD
Gilead announces agreement with PAHO for lenacapavir access
Premium
The Fly
Gilead announces agreement with PAHO for lenacapavir access
1M ago
GILD
Gilead price target raised to $175 from $155 at HSBC
Premium
The Fly
Gilead price target raised to $175 from $155 at HSBC
1M ago
GILD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >